Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by bioAffinity Technologies, Inc.

< Previous 1 2 Next >
bioAffinity Technologies Reports $2.4 Million Revenue for Q3 2024
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF BIAFW
bioAffinity Technologies Appoints New Chief Science Officer to Spearhead Product Development
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF BIAFW
bioAffinity Technologies Announces Award of Japanese Patent for CyPath® Lung
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF BIAFW
bioAffinity Technologies Announces Closing of $2.6 Million Registered Direct Offering & Concurrent Private Placement
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF BIAFW
bioAffinity Technologies Announces Pricing of $2.66 Million Registered Direct Offering & Concurrent Private Placement
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF BIAFW
bioAffinity’s CyPath® Lung Cancer Test Supported by Newly Published Flow Cytometry Guidelines
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF
bioAffinity Technologies Names J. Michael Edwards as Chief Financial Officer
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF
bioAffinity Technologies Awarded U.S. Federal Supply Schedule Contract for CyPath® Lung Test
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF
bioAffinity Technologies CFO to Depart for New Opportunity; J. Michael Edwards to Return as Interim CFO
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF BIAFW
Peer-Reviewed Study: bioAffinity Technologies’ CyPath® Lung Test Shows Potential Significant Healthcare Savings by Reducing Unnecessary Follow-Up, Medical Complications and Overdiagnosis
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF
bioAffinity Technologies Reports $2.4 Million Revenue for Q2 Driven by Growing CyPath® Lung Sales
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF BIAFW
bioAffinity Technologies Announces Closing of Registered Direct Offering, Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF BIAFW
bioAffinity Technologies Reports 217% Sales Growth in Second Quarter 2024 for CyPath® Lung
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF BIAFW
bioAffinity Technologies Announces Pricing of Registered Direct Offering and Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF BIAFW
bioAffinity Technologies Reports Accelerating Growth of Physician Practices Ordering CyPath® Lung Tests
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF BIAFW
bioAffinity Technologies Reports Record Q1 Revenue Driven by Accelerating Growth of CyPath® Lung Sales and Increased Laboratory Volumes
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF BIAFW
bioAffinity Technologies News Update
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF BIAFW
bioAffinity Technologies Advances New Product Development Initiatives to Accelerate Next Phase of Growth
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF BIAFW
bioAffinity Technologies Expands Campaign to Support American Cancer Society Initiative for Lung Cancer Screening
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF BIAFW
bioAffinity Technologies Reports Fourth Quarter and Full Year 2023 Financial Results
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF BIAFW
bioAffinity Technologies Announces Closing of $2.5 Million Registered Direct Offering and Concurrent Private Placement
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF BIAFW
bioAffinity Technologies Announces Pricing of $2.5 Million Registered Direct Offering and Concurrent Private Placement
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF BIAFW
bioAffinity Technologies Reports Accelerating Sales Growth of CyPath® Lung
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF
bioAffinity Technologies News Update
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF BIAFW
Medical Director of Lung Innovations Network and The Lung Center at Penn Highlands Healthcare, Sandeep Bansal, M.D., Joins bioAffinity Technologies’ Medical and Scientific Advisory Board and Incorporates CyPath® Lung into Medical Practice
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF
bioAffinity Technologies In The News
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF BIAFW
bioAffinity Technologies Appoints Jamie Platt, Ph.D., to its Board of Directors
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF BIAFW
CMS Posts Final Payment Determination for bioAffinity Technologies’ CyPath® Lung Effective January 2024
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF BIAFW
bioAffinity Technologies VP David Elzi, Ph.D., Named to American Society for Cell Biology Post
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF BIAFW
bioAffinity Technologies Teams with American Cancer Society to Raise Funds for Lung Cancer Screening
From bioAffinity Technologies, Inc.
Via Business Wire
Tickers BIAF
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.